In contrast, the DPP-4 inhibitor alogliptin helps prevent AF through different mechanisms: it increases angiogenesis, promotes nitric oxide (NO) production, prevents mitochondrial membrane depolarization, enhances mitochondrial function, and stimulates mitochondrial biogenesis [274,275]. This evidence concerns the gene DPP4 and atrial fibrillation.